Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash from Investing Activities (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Cash from Investing Activities for 2 consecutive years, with -$95000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 1483.33% to -$95000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$518000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$518000.0 for FY2025, 1338.89% down from the prior year.
  • Cash from Investing Activities hit -$95000.0 in Q4 2025 for Xilio Therapeutics, up from -$401000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$6000.0 in Q4 2024 to a low of -$401000.0 in Q2 2025.